Drug Trial Radar · NCT04656600
Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ
Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Mar 2, 2021
Primary completion
Oct 12, 2023
Study completion Oct 12, 2023
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective * To evaluate the efficacy on hematologic manifestations of imiglucerase treatment in Chinese patients who are diagnosed as Gaucher disease type Ⅲ * To evaluate the safety profile of imiglucerase in maximum dose in the label (60U/kg, IV biweekly) in Chinese patients. Secondary Objective * To evaluate the efficacy on viscera manifestations of imiglucerase treatment in Chinese patients who are diagnosed as Gaucher disease type Ⅲ * To evaluate the efficacy on bone disease of imiglucerase treatment in Chinese patients who are diagnosed as Gaucher disease type Ⅲ * To evaluate the effect on quality of life of imiglucerase treatment in Chinese patients who are diagnosed as Gaucher disease type Ⅲ
Conditions
- Gaucher's Disease
Interventions
Cerezyme® / ImigluceraseDrug
Pharmaceutical form: lyophilisate for solution for infusion Route of administration: intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in haemoglobinTime frame: Baseline to the end of 12 months
- Changes in platelet countTime frame: Baseline to the end of 12 months
- Adverse eventsTime frame: Baseline to the end of 13 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number : 107
Beijing, China
Investigational Site Number : 101
Beijing, China
Investigational Site Number : 104
Chengdu, China
Investigational Site Number : 102
Guangzhou, China
Investigational Site Number : 105
Guangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.